As far as we are aware, this new Arf1 inhibitor is the pioneering drug that activates a dual anticancer therapy by promoting cancer stem cell aging and anti‐tumor immunity and may lay the groundwork for additional therapeutics targeting this dual process. This evidence concerns the gene ARF1 and neoplasm.